THROMBOPROPHYLAXIS IN PATIENTS WITH IMHA: IS ACTIVE PREVENTION THE BEST MEDICINE?

摘要

Despite years of study into the best way to manage patients with immune-mediated hemolytic anemia (IMHA), articles published as recently as 2011 still document mortality rates of 30% to 40%. In her discussion "Thromboprophylaxis in immune-mediated hemolytic anemia," Sarah Helmond, BVSc, DACVIM, discussed the potential role of thromboprophylaxis (clot prevention strategies) in the management of these cases.